Foundayo (orforglipron) was FDA approved for weight loss on April 1, 2026 for adults with obesity or overweight with a weight-related health condition Foundayo is the only GLP-1 pill that can be taken once daily at any time no food or water restrictions required
The recommendations are nonbinding, and the FDA will make the final decision on whether to lift current restrictions
Compliance with national regulations governing health and nutritional claims is essential
Danning tablets might improve glucose and lipid metabolism in asymptomatic T2MD patients after cholecystectomy
Excessive growth hormone can lead to side effects such as joint pain, swelling, insulin resistance, and injection site reactions
Instead of fighting hunger and cravings all day, food choices often feel calmer, more natural, and easier to maintain